Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed LaboratoryCybin Corp. Is A Best In Class Psychedelics Company When Compared To Industry Bellwether Compass PathwaysMindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial AdvisorMind Medicine Inc. Launches First Of Its Kind Clinical Trials Using Synergistic Psychedelic CompoundsNuminus Wellness Is Building A World Class Psychedelic Research OrganizationHAVN Life Sciences Is Off To A Great Start Out Of The GateMydecine Innovations Group, Inc. to Create Special Committee for the Spin Out of US Related AssetsNuminus Announces Closing of Oversubscribed $4.6 Million OfferingRritual™ Announces Suite of Premium Functional Mushroom and Adaptogenic ElixirsCEO Spotlight: Doug Drysdale of Cybin Corp.Aion Therapeutic, Inc. Announces the Appointment of Dr. Herbert Fritsche, Former Professor of Laboratory Medicine and ChAWAKN Life Sciences Launches Clinical Research Division with Prof. David Nutt & Dr. Ben Sessa Identifying Suitable Apotheca Systems Reveals AI Platform for Psychedelic Assisted PsychotherapyPsychedelics Company Havn Life Announces Commencement of Public Trading on the CSEAion Therapeutic Files Five Patents with the United States Patent and Trademark OfficeCybin Corp Announces Doug Drysdale as Chief Executive OfficerCompass Pathways Is Set To Take Psychedelics Mainstream With An IPO On The NasdaqNuminus Files Restated Financial ReportsMydecine Innovations Group Has Put Together A World Class Organization From A Human Capital PerspectiveMindMed Announces First-Ever Clinical Trial Combining MDMA and LSD

AWAKN Life Sciences Launches Clinical Research Division with Prof. David Nutt & Dr. Ben Sessa Identifying Suitable Studies Across Europe & North America

Sep 9, 2020 • 11:59 AM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

AWAKN Life Sciences Inc (“AWAKN”), the European psychedelic assisted psychotherapy company, today announces the launch of its Commercial Clinical Research Division.

AWAKN’s purpose is broadening access to psychedelic assisted psychotherapy and integrating these services into mainstream mental healthcare in Europe across three business divisions of Clinical Research, Therapeutic Clinics, and Practitioner Training. AWAKN’s Commercial Clinical Research Division focuses on sponsoring, designing and delivering existing compound, new indication psychedelic assisted psychotherapy clinical trials, for both for profit and not for profit organisations.

Dr. Ben Sessa, AWAKN’s Chief Medical Officer, commented: “The world of psychedelic clinical research has been expanding at a staggering pace in recent years. It is unusual research that mostly comes from academic departments with private financial funding from philanthropic donations or private investors and a plethora of newly emerging small-scale psychedelic drug development start-ups – rather than from established pharmaceutical companies.”

“Our mission at AWAKN is to ensure that research in this field is done ethically, in a timely fashion and always with a direct focus on bettering patient care and continually driving increased accessibility for the masses. We are also keen on focusing on clinical problems that are significant public health issues, not just rare or unusual psychiatric disorders.”

“We are hugely excited about this launch of our Commercial Clinical Research Division, which enables AWAKN to work in partnership with both for profit and not for profit organisations to push the boundaries of psychedelic science and bring these essential medicines to the vast number of people who can benefit from them in these troubling times.”

Professor David Nutt, Chair of AWAKN’s Scientific Advisory Board, commented “The recent resurgence of interest in psychedelic medicine has been driven by neuroscience research leading to small translational medicine clinical trials. AWAKN’s Scientific Advisory Board has world-leading experts who have pioneered this research renaissance. We welcome the chance to progress further studies in new indications in this new venture.

Anthony Tennyson, Chief Executive Officer adds: “This is another key milestone achieved on our journey to becoming the leading UK and EU psychedelic assisted psychotherapy company. 17% percent of Europe’s population are affected by mental health issues annually so working with both profit / not for profit organisations to develop new clinical protocols will increase both the effectiveness of psychedelic assisted psychotherapy and the number of conditions that can be treated by psychedelic compounds.”

About AWAKN Life Sciences

AWAKN Life Sciences is a UK and EU focused company that is dedicated to integrating psychedelics into mental healthcare. We work across three business lines of clinical research, therapeutic clinics and practitioner training.

More Information

Anthony Tennyson | CEO |

Dr. Ben Sessa | CMO |

Share Share - Facebook Share - Twitter


Authored By

Michael Berger


Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.